volume 1 | issue 1 | jan - mar 2013 & pharmacokinetics · 2016. 4. 2. · laboratory manual of...

76
Biopharmaceutics & Pharmacokinetics A Practical Manual Compiled By: Deepa MK,M.Pharm., Assistant Professor, Department of Phrmaceutics, Nehru college of Pharmacy, Thiruvilwamala, Thrissur

Upload: others

Post on 26-Oct-2020

4 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

INTERNATIONAL JOURNAL OF

MEDICAL AND

SURGICAL EMERGENCIES

Volume 1 | Issue 1 | Jan - Mar 2013

SYDUS

ASIAN JOURNAL OF

HEALTH

SCIENCES

Volume 1 | Issue 1 | Jan - Mar 2013

SYDUS

Biopharmaceutics & Pharmacokinetics

A Practical Manual

Compiled By: Deepa MK,M.Pharm., Assistant Professor, Department of Phrmaceutics, Nehru college of Pharmacy, Thiruvilwamala, Thrissur

Page 2: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

INDEX

Sl .

No.

Date Experiments Page No. Marks Sig.

Data Analysis

1 Data Analysis I

2 Data Analysis II

3 Data Analysis III

4 Data Analysis IV

5 Data Analysis V

6 Data Analysis VI

Experiments

7 Determination of Partition Coefficient And Effect If

pH on Partition Coefficient of Salicylic Acid

8 Demonstration Of In Vitro One Compartment

Model After Administration Of Single IV Bolus

Dose Simulating Plasma Elimination And Urine

Excretion

9 Studies On Protein Binding Of Salicylic Acid

10 Diffusion Study Of Salicylic Acid By Using Egg

Membrane

11 In Situ Drug Absorption Study Of aspirin tablet By

Using Everted Chicken Ileum

12 Formulation And Evaluation Of Transdermal Patch

Of Paracetamol Using HPMC

13 Dissolution Study of Uncoated Marked Tablets

Page 3: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 1

CALCULATIONS

Time

( hrs)

Plasma

Concentration

(µg/ml )

Plasma

Concentration

X Time

0 0

0.5 5.4

1 10

2 17.2

4 25.8

8 29.6

12 26.6

18 19.4

24 13.3

36 5.9

48 2.6

72 0.5

Page 4: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 2

Exp.No:1 Date:

DATA ANALYSIS-I

AIM

To determine the pharmacokinetic parameters such as Cmax, tmax, KE, , t ½, ,

, , ,MRT , from the given data

.

DATA

Drug concentration in plasma, following oral administration of a fully absorbed 500mg dose

of a drug is given below.

Time

( hrs)

Concentration

(µg/ml )

0 0

0.5 5.4

1 10

2 17.2

4 25.8

8 29.6

12 26.6

18 19.4

24 13.3

36 5.9

48 2.6

72 0.5

Page 5: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 3

Page 6: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4

1. Cmax : Peak plasma level computed directly from the plasma level profile.

2. t max: Time to achieve peak plasma level computed directly from the plasma level

profile.

3. Elimination rate ( KE):Elimination rate constant is calculated from the terminal

elimination phase of log plasma concentration Vs time by least square regression analysis. KE

is calculated as KE = 2.303 × Slope

4. Biological Half-life ( t 1/2)

t ½

5.

The extent of absorption is calculated from area under the plasma concentration is calculated

from area under the plasma concentration- time profile from zero to t* by trapezoidal rule.

6.

The estimation of area under the blood level time curve from zero time to infinity must be

carried out in 2 steps.

1. The area under the curve from zero to time t* is calculated by means of trapezoidal

rule.

2. The area under curve from t* to infinity by using formulae

where = 2.303 times the slope of terminal exponential phase of a plot of log

plasma concentration Vs time

t* = time at which blood sampling is stop

C* = concentration of drug at t*

Page 7: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 5

Page 8: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 6

7.

Plot of the product of concentration and time Vs time from zero time to t* is often

referred to as the area under the first moment curve.

8.

The estimation of area under first moment curve from zero time to infinity must be carried

out in 2 steps.

1. The area under first moment curve from zero to time t* is calculated by means of

trapezoidal rule.

2. The area under first moment curve from t* to infinity by using formulae

= 2.303 times the slope of terminal exponential phase of a plot of log plasma

concentration Vs time

t* = time at which blood sampling is stop

C* = concentration of drug at t*

9. Mean Residence Time ( MRT ):it is defined as the average amount of time spent by the

drug in the body before being eliminated.

MRT =

Page 9: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 7

Page 10: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 8

REPORT

1. Cmax

2. t max

3. KE

4. t 1/2

5.

6.

7.

8.

9. MRT

REFERENCES

1.P L Madan. Biopharmaceutics and pharmacokinetics.1st edition; p.196-197

2. C.Vijayaraghavan ,Experimental biopharmaceutics and pharmacokinetics ,1st edition. P.61-

64

Page 11: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 9

Page 12: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 10

Expt.No:2 Date:

DATA ANALYSIS-II

AIM

To determine the pharmacokinetics parameters like KE , Vd,and C0 following 250mg

IV bolus administration of one compartment kinetics.

DATA

Time (hr)

Plasma

Concentration (µ/ml)

1 8

2 6.3

3 4.9

4 3.9

5 3.1

6 2.5

7 1.9

THEORY

In one compartment model, the body is considered as single, kinetically homogenous

unit that has no barriers to movement of drugs and final distribution equilibrium between the

drug in plasma and other body fluid is attained instantaneously and maintained at all times.

This method thus applied only to those drugs that distribute throughout the body.

Page 13: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 11

Page 14: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 12

One compartment model-Intravenous Bolus Administration

When a drug that distributes rapidly in the body is given in the form of a rapid

intravenous injection (i.e. i.v. bolus or slug), it takes about one to three minutes for complete

circulation and therefore the rate of absorption is neglected in calculations. The model can be

depicted as follows:

The general expression for rate of drug presentation to the body is

= Rate in (availability) – Rate out (elimination)------------------------ (1)

Since rate in or absorption is absent, the equation becomes;

= -Rate out ------------------------------------------------------------------(2)

If the rate out or elimination follows first-order kinetics, then:

= -KE X -----------------------------------------------------------------------(3)

Where KE = first-order elimination rate constant, X = amount of drug in the body at any time

t remaining to be eliminated and negative sign indicates that the drug is being lost from the

body. The various related pharmacokinetic parameters can now be estimated.

Elimination rate constant (KE)

For a drug that follows one compartment and administered as IV bolus injection, the decline

in plasma drug concentration is only due to elimination of drug from body ,the phase being

called as elimination phase.

Elimination half-life(t ½)

It is the time taken for the amount of drug in body as well as plasma concentration to decline

by one half or 50%of its initial value .in case of elimination process, biological half-life ie

Blood and other

Body tissue

Page 15: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 13

Page 16: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 14

Apparent volume of distribution (Vd)

It is the measure of extent of distribution of drug and is expressed in litre.

Vd = X0/C0

Where X 0 is dose administered, C0 is initial plasma concentration.

REPORT

Elimination rate constant (KE) =

Volume of distribution (Vd) =

Elimination half-life (t1/2) =

Initial concentration (C0) =

REFERENCES

1.D.M Brahmankar, Sunil B. Jaiswal, Biopharmaceutics and Pharmacokinetics A Treatise,

First edition , Vallabha Prakashan, Delhi, 2006, P.290 - 292

Page 17: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 15

Page 18: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 16

Expt:3 Date:

DATA ANALYSIS-III

AIM

To determine absorption rate constant from given oral absorption data given by using

method of residuals.

DATA

Time

( hrs)

Plasma

Concentration

(µg/ml )

1 0.38

2 0.73

3 0.91

4 0.97

5 0.97

6 0.92

8 0.71

10 0.53

12 0.40

14 0.30

THEORY

The absorption rate constant can be calculated by methods of residuals and the technique is

also known as feathering,peeling,,stripping or curve fitting.it is commonly used in

pharmacokinetics to resolve a multi exponential curve in to its individual components. For a

drug that follows one compartment kinetics and administrated orally, the concentration of

drug in plasma is expressed by,

Page 19: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 17

CALCULATIONS:

Time

( hrs)

Concentration

(µg/ml )

Extrapolated

Concentration

(µg/ml )

Residual

Value

1 0.38

2 0.73

3 0.91

4 0.97

5 0.97

6 0.92

8 0.71

10 0.53

12 0.40

14 0.30

Page 20: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 18

- ----------------------------------------------(1)

, a hybride constant ,then

C = - ----------------------------(2)

During the elimination phase, when absorption is almost over Ka>>KE and the value of 2nd

exponential approaches zero whereas, first exponential retains some finite

value.

At this time equation (2 )reduces to,

-------------------------------(3)

In log form above equation is

-----------------------------(4)

Where C Represents the back extrapolated plasma concentration values.a plot of log c

versus t yields a biexponential curve with a linear phase having slope –KE/2.303,back

extrapolation of this straight line to time zero yields y-intercept equal to log A.

Subtraction of true plasma concentration value i.e. equation.(3) from equation (4) yields a

series of residual concentration values Cr.

-----------------------(5)

In log form, the equation is:

----------------------(6)

Page 21: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 19

Page 22: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 20

A plot of log Cr Versus t yields a straight line with slope -Ka/2.303 and y-intercept logA.

Absorption half-life can then be computed from Ka using the relation 0.693/Ka. Thus,

the method of residuals enables resolution of biexponential plasma level-time curve into

its two exponential components.

Solution:

1.plot plasma drug concentration on Y-axis time and on x-axis in a semilogarithmic graph

paper.

2.back extrapolate the log linear of residual portion of the decline phase. Let ‘C’ denotes the

plasma concentration alone this extrapolated line.

3.sustract the absorbed plasma concentration (C) from corresponding extrapolated value at

each time point.

4.plote the residual (C- C ) against time on the same semilogarithemic graph paper.

If the residual plot is an straight line ,then the absorption is 1st order process.the slope is equal

to-Ka/2.303,

Ka=slope ×2.303.

REPORT

The absorption rate constant from the given oral absorption data was found to be

REFERENCES

1. C.Vijayaraghavan,Experimental biopharmaceutics and pharmacokinetics 1st edition ,P.113-115

Page 23: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 21

Page 24: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 22

Expt No: 4 Date:

DATA ANALYSIS-IV

AIM

To determine absorption rate constant, elimination rate constant, Tmax, Cmax and

volume of distribution from given data.

DATA

Drug concentration in plasma at different time interval following oral admiration of

100mg of drug is given below by assuming that administrated dose is fully absorbed.

Time

( hrs)

Plasma

Concentration

(µg/ml )

0.25 1.6

0.5 2.7

1 3.7

2 3.5

3 2.7

4 2

6 1.02

8 0.49

10 0.26

12 0.12

Page 25: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 23

CALCULATIONS:

Time

( hrs)

Plasma

Concentration

(µg/ml )

Extrapolated

Concentration

(µg/ml )

Residual

Value

0.25 1.6

0.5 2.7

1 3.7

2 3.5

3 2.7

4 2

6 1.02

8 0.49

10 0.26

12 0.12

Page 26: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 24

REPORT

Absorption rate constant :

Elimination rate constant:

Tmax :

Cmax :

Volume of distribution :

REFERENCES

1.S.B.Bhise, R.J.Dias et.al, Laboratory manual of biopharmaceutics and

pharmacokinetics, first edition, Trinity publishing house, Satara, p.132

Page 27: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 25

Page 28: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 26

Expt .No: 5 Date:

DATA ANALYSIS-V

AIM

To determine elimination rate constant and excretion rate constant from given urinary

excretion data by excretion rate method.

DATA

Sample

Time of urine

collection(hr)

Volume of

urine

collected(ml)

Concentration

of unchanged

drug in

urine(mcg/ml)

1 0-2 140 250

2 2-4 150 100

3 4-6 90 80

4 6-8 20 20

5 8-12 310 10

6 12-24 600 4

Page 29: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 27

CALCULATIONS:

Sample

Time of

urine

collection

(hr)

Volume

of urine

collected

(ml)

Concentrati

on of

unchanged

drug in

urine(mcg/

ml)

Urine

Collectio

n Interval

(ðd)

midpoint

of urine

collection

(t*)

amount

excreted

in tine

interval

(mg)

excretio

n rate

(mg/hr)

1 0-2 140 250

2 2-4 150 100

3 4-6 90 80

4 6-8 20 20

5 8-12 310 10

6 12-24 600 4

Page 30: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 28

REPORT

Elimination rate constant :

Excretion rate:

REFERENCES

1. D.M Brahmankar, Sunil B. Jaiswal, Biopharmaceutics and Pharmacokinetics A Treatise,

First edition , Vallabha Prakashan, Delhi, 2006, P.

Page 31: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 29

Page 32: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 30

Expt No:6 Date:

DATA ANALYSIS-VI

AIM

To determine elimination rate constant from given urinary excretion data by Sigma

Minus method.

DATA

Sample

Time of urine

collection(hr)

Volume of

urine

collected(ml)

Concentration

of unchanged

drug in

urine(mcg/ml)

1 0-2 140 250

2 2-4 150 100

3 4-6 90 80

4 6-8 20 20

5 8-12 310 10

6 12-24 600 4

Page 33: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 31

CALCULATIONS

Samp

le

Time

of

urine

collect

ion

(hr)

Volu

me of

urine

collect

ed

(ml)

Concen

tration

of

unchan

ged

drug in

urine(

mcg/ml

)

Urine

Collec

tion

Interv

al

(ðd)

midpoint

of urine

collectio

n

(t*)

amou

nt

excre

ted in

tine

inter

val

(mg)

excretio

n rate

(mg/Hr)

Cumula

tive

amount

excrete

d

(mg)

Amou

nt

reami

ng to

be

excret

e

(mg)

1 0-2 140 250

2 2-4 150 100

3 4-6 90 80

4 6-8 20 20

5 8-12 310 10

6 12-24 600 4

Page 34: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 32

REPORT

The elimination rate constant was found to be _________________from the given

urinary excretion data by Sigma Minus method.

REFERENCES

1.D.M Brahmankar, Sunil B. Jaiswal, Biopharmaceutics and Pharmacokinetics A Treatise,

First edition , Vallabha Prakashan, Delhi, 2006, P.

Page 35: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 33

Page 36: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 34

Expt No:7 Date:

DETERMINATION OF PARTITION COEFFICIENT AND EFFECT OF pH ON THE

PARTITION COEFFICIENT OF SALICYLIC ACID

AIM

To determine the partition coefficient of salicylic acid and effect of PH on partition

coefficient of salicylic acid.

MATERIAL REQUIRED

Salicylic acid, n-octanol, potassium dihydrogen phosphate, FeNO3 solution, colorimeter

separating funnels.

PRINCIPLE

According to pH partition hypothesis the gastrointestinal epithelial act as a lipid

barrier towards drug which are absorbed by passive diffusion and those that are lipid soluble

will pass across the barrier as much drugs are weakly acidic or basic drug will pass across the

gastro intestinal epithelia is impermeable to the ionized form of some drug. The extent to

which a weakly acidic drugs or basic drugs ionized in solution in the gastro intestinal fluid

may be calculated by using HINDERSON HESSELBATCH equation. Drugs having a single

ionisable group [Aspirin/ salicylic acid]. The equation takes the focus on

Log [A]/[HA] = pH = PKa

Where

PKa = negative logarithm of acid dissolution constant

[HA] = concentration of unionized form

[A] = concentration of ionized form

PH =P

H of GIT tract

For week basic drug log[BH]/[B]=PKa-pH

Where

[BH]=concentration of un ionized form

[B] =concentration of ionized form

According to the equation of weakly acidic drug PKa-3.6 will be

predominantly consider at GI fluid at PH

1.2(98.4%) and almost totally considered in

intestinal fluid at pH 6.8(98.8%) where a weakly basic drug PKa 5 will almost entirely

consider (99.8%) at gastric pH or 6.8(98.4%)

Page 37: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 35

Page 38: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 36

PROCEDURE

Preparation Of Standard Graph Of Salicylic Acid

1. 100 mg of salicylic acid is weighed and transfered into 100ml standard flask and make up

the volume upto 100mi using distilled water(stock solutionA)

2. From the stock solution a various strength of concentration like 20,40,60,80&100

microgram per ml are prepared by taking 2,4,6,8&10ml from the stock solution A and

diluting upto 100 ml by using distilled water

3. From corresponding concentrations pipette out 5 ml and add 2.5mi of 4 % FeNO3

solution

4. Measure the absorbance at 547nm by means of colorimeter. Standard graph is plotted by

taking concentration of salicylic acid on X axis and the absorbance at 547nm on Y axis

Determination Of Partition Coefficient

1) Four separating funnels are taken clean thoroughly and dry

2) The separating funnels are named as F1,F2,F3&F4

3) 25ml o0f 2.2 pH buffer is added and 25 ml of n-octanol is added to separating funnel F1

100mg of salicylic acid is added to the separating funnel and allow to separate & 1ml of

aqueous layer is removed and transferred into standard flask and make upto 100ml From

this solution 5ml is taken and add 2.5 ml of 4% FeNO3 solution is added. The absorbance

is measured at 547 nm by taking 2.5ml of FeNO3 solution and 5ml water as blank

4) Take 25ml of n-octanol and 25ml of pH4 buffer solution and procedure is repeated

at pH 7.2& 8 in separating funnels F3 & F4

5) The absorbance at different pH and concentration of salicylic acid are taken and noted

down from the standard graph and the value is multiplied by multiplying factor

REPORT Partition coefficient of given drug of salicylic acid and effect of pH on

partition coefficient was noted

Partition coefficient at pH 2.2 =

Partition coefficient at pH 4 =

Partition coefficient at pH 7.2 =

Partition coefficient at pH 8 =

Partition coefficient at pH 10 =

REFERENCES

. C.Vijayaraghavan and Judith Justin. Experimental biopharmaceutics and pharmacokinetics 1st edition ,P.4-9

Page 39: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 37

Page 40: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 38

Expt No:8 Date:

DEMONSTRATION IN VITRO ONE COMPARTMENT MODEL AFTER

ADMINISTRATION OF SINGLE IV BOLUS DOSE SIMULATING PLASMA

ELIMINATION AND URINE EXCRETION

AIM

To study in vitro compartment modeling after administration of single IV dose

simulating plasma elimination and urinary excretion.

MATERIALS REQUIRED

Glass beakers, pipettes, test tubes, connecting tubes, UV -Vis Spectrophotometer etc.

PRINCIPLE

By an arrangement of beakers and a constant head water reservoir, it is possible to

simulate plasma concentrations and drug amounts in urine after IV bolus administration. The

constant flow of water through the system causes a first order kinetics. In this experiment

Salicylic acid is used as a model compound and its various pharmacokinetic parameters are

obtained by simulating the plasma elimination and urinary excretion after giving a single IV

bolus dose. The drug concentration can be determined spectrophotometrically at 547 nm, by

sampling the water from plasma compartment (P) and urine compartment (U) periodically.

The pharmacokinetic parameters of the system can be determined by analyzing the

obtained data.The plasma concentration versus time is plotted on semilog paper and the

parameters; elimination rate constant, elimination half life, plasma concentration at zero time

(C0 ), volume of distribution, clearance and area under curve can be determined. The rate of

excretion versus time is plotted on semilog paper and parameters elimination rate constant,

excretion rate constant and elimination half life can be determined.

Models are used to describe and interpret a set of data obtained by experimentation.

Pharmacokinetic model provide concise means of expressing mathematically or

quantitatively, the time course of drug throughout the body and compute meaningful

pharmacokinetic parameters. Three different approaches to pharmacokinetic analysis for

experimental data are compartment modeling, non-compartmental analysis, physiologic

modeling. A compartment is an entity, which can be described by definite volume and

concentration.

Page 41: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 39

Page 42: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 40

In the case of IV bolus administration the drug distributes rapidly in the body. The

disposition of a drug follows one compartment kinetic model and it is monoexponential and

the equation is

Dв= Dв0. E־

kE

t (or) log Dв = -kEt/2.303 + log Dв

0

Dв = Amount of Drug in the body.

Dв0= Amount of drug at zero time.

KE = Elimination rate constant.

It is a pharmacokinetic parameter that permits the use of plasma drug concentration (Cp) in

the place of Dв. In terms of volume of distribution.

Cp0= Dвº/Vd (or) Vd= Dвº/Cp

0

DIAGRAM

Design of apparatus to simulate one compartment open model IV bolus dose

EXPERIMENTAL PROCEDURE

Set the plasma (beaker) and urine (measuring cylinder) components to the

apparatus.

Arranged such that the buffer is continuously pumping to the central compartment

( beaker) through peristaltic pump.

Page 43: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 41

Page 44: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 42

Set the beaker on the magnetic stirrer and adjusted for gentle mixing.

Established a flow rate of 8.4 ml/ minute.

Injected the plasma (beaker with the dose of drug salicylic acid (100mg).

Placed an empty measuring cylinder in position to collect the urine sample used

buffer (pH 7.4 phosphate buffer) as the blank.

Plasma sample: Collect (1ml) plasma sample at 0,5, 10, 15, 30,45, and 60 min

after the dose. The test tubes were arranged and labeled to accommodate the

samples. Diluted 1ml sample to 10ml with buffer.

Urine sample:Urine samples (1ml) were collected at 0,5, 10, 30, 45, and 60

minutes. At each time point for unit collection replace the beaker with empty

beaker. Measured the volume collected, mixed the contents of beaker to obtain a

uniform solution and diluted 1ml sample to obtain a uniform solution and diluted

1ml sample to 10ml for analysis. Each sample was analyzed using colorimeter at

547 nm.

Data Analysis:. Calculated Ke from urinary excretion data. Plot concentration vs

time on semi log graph paper and calculate KE from the slope, half life, Volume of

distribution, initial concentration and clearance.

REPORT

Elimination rate constant, (KE) =

Excretion rate constant, (Ke) =

Volume of distribution, (Vd) =

Initial plasma drug concentration, (C0) =

REFERENCES

1.Leon Shargel et.al, Applied Biopharmaceutics and Pharmacokinetics. 5th

edition; Mc Graw

Hill Companies, Singapore, 2005, P. 51 - 70

Page 45: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 43

Page 46: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 44

Exp.No:9 Date :

STUDIES ON PROTEIN BINDING OF SALICYLIC ACID

AIM

To determine the percentage of salicylic acid that undergoes protein binding across a

semipermable membrane.

REQUIREMENTS

Salicylic acid, egg albumin, ferric nitrate, hydrochloric acid, egg membrane, and distilled

water. standard flask, beaker, open end tube UVspectrophotometer, magnetic stirrer,

PRINCIPLE

A drug in the body can interact with several tissue components of which two major

categories are blood and extra-vascular tissues. The phenomenon of complex formation of

drugs with protein is called protein binding of drugs. Binding to Plasma Proteins like

Albumin affects drug distribution and elimination as well as the pharmacological effect of the

drug. Only that fraction of the drug concentration that is freely circulating or unbound can

penetrate cell membrane and is subjected to glomerular filtration. The most important

contribution to drug binding in the plasma is made by albumin, which comprises. About half

of total the plasma proteins, albumin binds a wide variety of drug molecules but plays an

important role binding of weak acids and neutral drugs.

In this experiment, Tube A contains only Salicylic acid with no protein in it. The

equilibrium of Salicylic acid in tubeA and beaker is achieved through semipermeable

membrane and the concentration of Salicylic acid in beaker can be measured. However, Tube

B contains Salicylic acid in presence of protein (0.5 ml egg albumin) and hence the protein

binding of Salicylic acid takes place. This allows only free Salicylic acid left after protein

binding to equilibrate through semipermeable membrane, which reduces the concentration of

Salicylic acid in beaker.Further, reduction in concentration of Salicylic acid takes place in

tube C because of increased presence of protein (1 ml egg albumin). This increases protein

binding of salicylic acid, thereby reducing free Salicylic acid in the tube and in beaker

too.Salicylic acid present in beaker (non protein compartment) is estimated by adding ferric

Page 47: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 45

Table1. Calibration curve of salicylic acid

Concentration Absorbance

At 547nm

10

20

30

40

50

60

Page 48: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 46

nitrate solution. The reaction of Salicylic acid with ferric nitrate produces an intensely

colored complex, whose maximum absorbance can be detected at 540nm

spectrophotometrically.

The fraction of drug unbound (FU) in plasma is given as

FU = Concentration of unbound drug in plasma

Total plasma drug concentration

PROCEDURE

Calibration Curve Of Salicylic Acid:

Preparation of colouring agent: Dissolve ferric nitrite (4g) in100ml distilled

water.

Preparation of standard stock solution: weigh accurately 100 mg of salicylic

acid and dissolve in 100ml of distilled water using 5ml alcohol. Take 10 ml of this

solution and dilute to 100ml with water.

Preparation of working solution: from stock solution, pipette out 0.2, 0.4, 0.6,

0.8 and 1 ml into 10ml volumetric flask and add 4ml colouring agent. Dilute

resulting solution to 10ml with water to get concentration in range of 2 to

10mcg/ml.

Measure the absorbance: record absorbance of the working solution of salicylic

acid at ʎmax of 540nm using UV visible spectrophotometer against water as blank.

Plot a graph of absorbance versus concentration.

Protein binding study of drug

Take three hollow tubes and mark them as A, B and C.

To one end, tie a semipermeable membrane in such a way that a sack is formed.

Place 1ml of 0.1%Salicylic acid and 1ml of distilled water in tube A.

Place 1ml of 0.1%Salicylic acid and 0.5 ml of egg albumin and 0.5 ml distilled water

in tube B.

Place 1ml of 0.1% Salicylic acid and 1ml of egg albumin in tube C.

Page 49: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 47

OBSERVATIONS

Table 2. Percent cumulative drug release with and without protein through egg

membrane

Time(min)

Percent

cumulative

drug release

Tube A Tube B Tube c

10

20

30

40

50

60

CALCULATIONS

A.Determination of unknown concentration of Salicylic acid

Determine unknown concentration of Salicylic acid from receptor compartment by using

following equation

Y=mX+c

Where,Y= absorbance,m= slope,X= concentration, c = the intercept.

B.Amount of drug diffused (mg)

Amount of drug diffused =[Concentration ( µ/ml) x (volume of diffusion medium) x

(dilution factor)]/1000

C. Dilution factor

Dilution factor = volume of diluted sample (ml) / volume of sample removed (ml)

D. Percent cumulative drug release

Percent cumulative drug release = (amount of drug diffused x 100) /total amount of

dose

Page 50: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 48

Place the tubes in a 50 ml of distilled water and pipette out 5 ml of sample from

beaker at the intervals of 15,30, 45, 60, 75 and 90 min.

Add 4ml of coloring agent and 1ml of distilled water and determine absorbance at 540

nm. Replace the fluid with 5ml of distilled water in the beaker.

Plot comparative curves of amount of Salicylic acid present in non protein

compartment versus time.

RESULT

The percent release of Salicylic acid without any proteins was found to be _______,

with 0.5 ml of egg albumin was______, and with 1ml of egg albumin was_______.

REFERENCES

1.S.B.Bhise, R.J.Dias et.al, Laboratory manual of biopharmaceutics and

pharmacokinetics, first edition, Trinity publishing house, Satara, p.66-70

Page 51: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 49

Page 52: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 50

Exp.No: 10 Date:

IN SITU DRUG ABSORPTION STUDY OF SALICYLIC ACID BY USING

EVERTED CHICKEN ILEUM

AIM

To perform in vitro absorption-permeation study of aspirin tablet .

REQUIREMENTS

Glasswares: Beaker, test tube, funnel, volumetric flask, etc.

Chemicals: Sodium lauryl sulphate, phosphate buffer pH 5, distilled water, Krebs ringer

solution pH 7.4,ferric chloride and Aspirin tablet

Instruments:Weighing balance, dissolution apparatus,UVspectrophotometer

THEORY

Good oral bioavailability occurs when the drug has maximum permeability and

maximum solubility at the site of absorption. The extent of absorption of drug , thus, could be

predicted based on permeability and solubility measurements. Hence, the intestinal

permeability represents one essential part in the prediction of oral bioavailability.The

intestinal permeability data can be used in preformulation studies to evaluate the effects of

various pharmaceutical excipients on drug absorption. A number of in vitro methods for

assessing the intestinal permeability of a given drug have been developed. absorption

(permeability) studies based on isolated intestinal sacs are routinely performed. The

advantages of this model are that it contains all the types of cells and mucus layer; it is

relatively fast and inexpensive; and it can be used for preformulation studies. This kind of

model is suitable for measuring kinetic parameters with high reliability and reproducibility

The chicken small intestine could be a useful model for intestinal absorption based on the

assumption that membrane permeability of drugs is not species-dependant, since the

composition of plasma membrane of intestinal epithelial cells is similar across the species.

Thus the permeability across the chicken intestinal segment could be expected to be the same.

Furthermore, the model would have advantages as less labor intensive, less time consuming,

Page 53: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 51

Page 54: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 52

lower cost per assay and, since slaughtered chicken is used, no special permission from

animal ethical committees would be required

Design of continuous dissolution-absorption system using everted intestine segment

The in vitro continuous dissolution absorption system design is illustrated in Figure 1. The

system consists of USP dissolution apparatus 1 and a side-by-side perfusion apparatus

holding isolated everted intestine segment. In this system, drug dissolution from the slow

release tablet and permeation across everted intestine occurs simultaneously. Use 1000 ml of

distilled water as dissolution medium maintained at 37 ± 0.5 °C. The perfusion apparatus is

consisted of two glass tubes,Aand B, connected together (Figure 1). Tube B is a bent cannula

at its lower end, and tube A, a straight cannula at its lower end. The distance between two

cannula is kept constant. The isolated everted intestinal segment is fixed between the ends of

tubesAand B as shown in the figure 1. The ends of the intestine are tied in position with a

thread. The apparatus is immersed completely into the dissolution vessel.

Figure 1. Design of in vitro continuous dissolution-absorption system

Labels:1. Dissolution flask, 2. Rotating shaft, 3. Dissolution medium, 4. Basket, 5. Tablet, 6.

Oxygen tube, 7.

Tube B, 8.TubeA, 9. Everted intestine, I. Dissolution absorption system, II.Absorption

(perfusion) apparatus.

Page 55: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 53

Page 56: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 54

PROCEDURE

Preparation of solution:

Krebs ringer solution: Prepare the Krebs ringer solution by combining 6.3 g NaCl, 0.35 g

KCl, 0.14 g CaCl , 0.16 gKH PO , 0.15 gMgSO ·7H O, 2.1 gNaHCO , and 5 g glucose in one

liter of distilled water.

Plotting of calibration curve

Transfer accurately weighed 100 mg of Acyclovir in to 100 ml volumetric flask containing

sufficient quantity of phosphate buffer pH 5.0. Finally adjust volume to get stock solution

containing 100 μg/ml Aspirin Withdraw adequate quantities of aliquots from standard stock

solution in 10 ml volumetric flask and dilute with distilled water to get the concentration of 2,

4, 6, 8, 10, 12, 14, 16, 18 and 20 μg/ml of aspirin. Measure the absorbance of these dilute

solutions at a max of 547 nm by using double beam UV spectrophotometer against a blank .

Plot the graph of absorbance versus concentration and determine slope, intercept and

coefficient of correlation.

Isolation of everted intestine

Bring male white Leghorn chicks weighing between 500 and 600 g from the local market.

For isolation of everted intestine, slaughter the chicks, perform a median incision of the

abdomen and free the small intestine. Clean the lumen carefully from mucus by rinsing with a

pH 7.4 buffer solutions (Krebs ringer solution).Remove an intestinal segment of the first 6 cm

length and transfer to oxygenated Krebs ringer solution. Wash it thoroughly with warm Krebs

ringer solution. Turn back the proximal extremity of the intestine and ligate on a glass rod to

form an everted bag. Alternatively, chick intestine can be obtained from slaughter house by

taking proper care of providing oxygenated Krebs ringer solution to intestinal segment

removed. This will eliminate the requirement of taking permission of Ethics Committee for

performing this experiment.

Dissolution absorption studies

1.Maintain the dissolution medium consisting of 900 ml of phosphate buffer pH 5.0 at 37 ±

0.5 °C. Clamp a fresh intestinal segment to perfusion apparatus, as shown in the figure 1

2. Fill Krebs ringer solution in perfusion apparatus and record total volume of absorption

compartment (tube A and tube B of perfusion apparatus).

Page 57: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 55

3. Place the perfusion apparatus into dissolution medium and aerate it.

OBSERVATION

Table 1. Percent cumulative drug release(%CDR)

Time(min) Absorbance

At 537nm

Concentration Cumulative

amount of drug

release (mg)

CADD/unit

area

5

10

15

20

25

30

Table 2.Amount of Aspirin diffused

Time(min) Absorbance

At 537nm

Concentration Cumulative

amount of drug

diffused (mg)

CADD/unit

area

10

20

30

40

50

60

Page 58: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 56

4. Place aspirin tablet into basket and rotate it at 50 rpm.

5. Withdraw 2 ml sample at interval of 10 min up to 120 min and determine released aspirin

spectrophotometrically at 537 nm.

6.Withdraw the transported drug from absorption compartment with replacement of Krebs

ringer solution at 13 min to 123 min at the interval of 10 min and analyze it

spectrophotometrically for transported Aspirin at 537 nm. To allow time for drug to circulate

from the dissolution vessel to the everted intestine surface, absorption samples should be

collected 3 min later than their corresponding dissolution samples.

7. Repeat whole experiment in triplicate (n=3) using fresh dissolution medium as well as

fresh intestinal segment each time.

8. Plot the graph of percent drug released versus time.

9. Plot the graph of cumulative amount of drug diffused versus time and determine slope of

linear portion as steady state appearance rate (mg/min) namely the amount of a compound

traversing the tissue in time t (min).

Page 59: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 57

CALCULATIONS:

1. Concentration of diffused drug ( g/ml)

Plot the graph of absorbance versus concentration and determine slope and intercept.

Y=mX+ c

Where,Y=absorbance,m=slope,X=concentration ( g/ml), c = intercept.

2. Cumulative amount of drug diffused (mg)

Cumulative amount of drug diffused (CADD) =

[Concentration ( g/ml) x (volume of diffusion medium) x (dilution factor)]/1000

Surface area (A) of chicken intestine (cm )

A=2 rl

Where, r = internal radius of everted intestine, l = length of everted intestine.

4. Dilution factor

Dilution factor = volume of diluted sample (ml)/ volume of sample removed (ml)

5.Amount of drug released in dissolution medium (mg)

Amount of drug released =

[Concentration ( g/ml) x (volume of dissolution medium) x (dilution factor)]/1000

6. Percent cumulative drug release

Percent cumulative drug release = (Amount of drug released) x (100 /strength of tablet)

7.Apparent permeability (cm/s)

Where, dQ/dt = steady state appearance rate, namely the amount of a compound traversing

the tissue in

time t (min), A = exposed area of the tissue (cm ), C = initial concentration of the drug in the

donor

compartment.

Page 60: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 58

REPORT

1.Percent drug release of marketed aspirin tablet in phosphate buffer is _________%in 2 hr.

2.Amount of Aspirin diffused through intestinal membrane is _________ in 2hr

REFERENCES

1.S.B.Bhise, R.J.Dias et.al, Laboratory manual of biopharmaceutics and

pharmacokinetics, first edition, Trinity publishing house, Satara, page no:41-46

Page 61: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 59

CALCULATIONS;

1. Determination of concentration of diffused drug ( g/ml)

Plot the graph of absorbance versus concentration and determine slope and intercept.

Y=mX+ c

Where,Y= absorbance,m= slope,X= concentration ( g/ml), c = intercept.

2. Cumulative amount of drug diffused (mg)

Cumulative amount of drug diffused (CADD) =

[Concentration ( g/ml) x (volume of diffusion medium) x (dilution factor)]/1000

3. Surface area (A) of cellophane membrane

A= r

Where, r = radius of cellophane membrane exposed to diffusion medium.

4. Cumulative amount of drug diffused per unit area (CADD/cm )

CADD/cm = CADD/Area of cellophane membrane

5. Dilution factor

Dilution factor = volume of diluted sample (ml)/ volume of sample removed (ml)

6. Flux (J )

Slope (J ) of linear portion of plot of amount of drug diffused per unit area versus time.

7. Permeability coefficient (K )

KP = Jss/c

Where,C = initial concentration of the drug in donor compartment (mg)5

Page 62: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 60

Exp.No: 11 Date :

DIFFUSION STUDY OF SALICYLIC ACID BY USING EGG MEMBRANE

AIM

To study the in vitro permeation of paracetamol.

REQUIREMENTS

Paracetamol solution (100µg/ml), egg membrane, 100ml phosphate buffer of pH 5.8,

magnetic stirrer.

PRINCIPLE

The in vitro permeation of drug can be studied by open end tube with one end tied

with egg membrane. The open end tube is made of glass with a contact area of 3.8cm2. The

drug solution is taken in a open end tube which is immersed in a beaker containing phosphate

buffer of pH 5.8.The solution in beaker is continuously stirred by means of a magnetic stirrer

. Solution samples, 10 ml aliquots, are withdrawn from the beaker at various time intervals.

The beaker is refilled with phosphate buffer of pH 7.8 to keep the volume constant during the

experiment.

PROCEDURE

Calibration curve of Paracetamol in phosphate buffer of pH 5.8

Transfer 100mg of paracetamol to 100ml standard flask and make up the volume with

phosphate buffer of pH 5.8.

Take 1ml of prepared solution and make up to 100ml.

Take 10ml of above solution and make up to 100ml.

Then take 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 and make up to 10ml and the

absorbance was noted at 243nm UV Spectrophotometrically.

Page 63: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 61

Table1. Calibration curve of paracetamol

Concentration Absorbance

At 243nm

10

20

30

40

50

60

Table 2. Permeation of paracetamol through egg membrane

Time(min) Absorbance

At 243nm

Concentration Cumulative

amount of drug

diffused (mg)

CADD/unit

area

10

20

30

40

50

60

Page 64: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 62

In vitro release and permeation

Taken an open end tube which is tied with an egg membrane at one end.

Then add 10.0ml of 100mcg/ml solution of paracetamol to the open end tube.

It is kept in contact with a 100.0ml phosphate buffer at pH 5.8 and 10 ml of sample

was taken at an interval of 0.5, 1, 1.5, 2 hours respectively.

The absorbance of the given solution was observed at 243nm spectrophotometrically.

Then the concentration was determined from the plotted calibration curve.

The cumulative amount of drug diffused is calculated and then CADD/unit area is

determined.

A graph is plotted by taking CADD/unit area in y-axis and time in x-axis.

The slope of the graph will given the flux JSS.

Then permeability coefficient is determined by dividing flux with initial

concentration.

REPORT

Permeability coefficient and flux of paracetamol through egg membrane was found to be

and respectively.

REFERENCE

1.S.B.Bhise, R.J.Dias et.al, Laboratory manual of biopharmaceutics and

pharmacokinetics, first edition, Trinity publishing house, Satara, p.62-65.

Page 65: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 63

Page 66: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 64

Exp.No:12 Date :

FORMULATION AND EVAULATION OF TRANSDERMAL PATCH OF

PARACETAMOL USING HPMC

AIM

To formulate and carry out in vitro diffusion study of transdermal patch of paracetamol.

MATERIALS REQUIRED

Paracetamol, HPMC, glycerin

PRINCIPLE

Transdermal Drug delivery systems are the novel controlled drug delivery devices

where the device is formulated as patch that is applied on to the skin. Transdermal drug

delivery offers a route, which bypasses the hepatic first pass metabolism by providing the

drug in a controlled manner across the skin into the systemic circulation. Transdermal drug

delivery route can be applied to a wide variety of therapeutic categories of drug like Anti-

anginals, Anti-Hypertensives, Anti-inflammatories, proteins and peptide drugs etc. poorly

soluble drugs are represented by low absorption and weak bio-availability. One possibility of

increasing the solubility is the reduction of particle size. However, the fine particle may not

always produce the expected faster dissolution and absorption. These problems require better

technologies in processing new drug delivery system. Solid dispersion of solution method can

be used for these purpose, solid dispersion refers to dispersion of one or more active

ingredients in an inert carrier or matrix at a solid stae. Solid dispersion can be prepared by

melting (fusion) method. The solid dispersion may also be called solid state dispersion. The

term co-precipitate has been used to those preparations obtained by solvent.

PROCEDURE

The film was prepared by dissolving the 4% Hydroxyl propyl methyl cellulose by

continuous stirring.

Added 0.5 ml of glycerin into the above solution.

100mg of Paracetamol was incorporated and stirred thoroughly until the drug is

continuously dissolved.

Page 67: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 65

Page 68: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 66

Removed the air bubbles by ultra sonification.

Pour the above mixture into the mould.

Dried at room temperature for 24hours.

EVALUATION

A patch of 1cm2 area was taken and extracted with 5ml of distilled water and 1ml of the

above solution was taken and absorbance was measured at 257nm and the amount of drug

present in 1cm2

area of patch was calculated.

PHYSICAL EVALUATION

Percentage moisture loss

The films were weighed accurately and kept in a desiccators containing anhydrous

calcium chloride. After 3days, the films were taken out and weighed. The moisture loss

was calculated using the formula:

% moisture loss =final weight – initial weight × 100

Initial weight

Folding endurance

The folding endurance was measured manually for the prepared films. A strip of films

(3×4 cm) was repeatedly folded at the same place till it broke. The number of times the

film could be folded at the same place without breaking/cracking gave the value of

folding endurance.

Mass variation

The patches were subjected to mass variation by individually weighing 10 randomly

selected patches. Such determinations were carried out for each formulation.

RELEASE STUDIES

In vitro diffusion study

In vitro diffusion study was carried out by using Franz- diffusion cell. In this method

egg membrane is used as model membrane.

Page 69: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 67

Page 70: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 68

The membrane was placed between the donor compartment and the reservoir

compartment (phosphate buffer pH 5.8).

The patch was placed on the membrane and the compartments clamped together.

The receptor compartment (70ml capacity) was filled with phosphate buffer of pH 5.8

and hydrodynamics in the receptor compartment was maintained by stirring with a

magnetic bead at 100rpm.

5ml of sample is withdrawn and replaced with receptor medium.

Amount of drug present is assayed spectrophotometrically at 243nm and amount of

drug release at various time intervals was calculated.

REPORT

REFERENCE

1.Pravin Gavali et al Design and development of hydroxypropyl methylcellulose (HPMC)

based polymeric film of Enalapril maleate Int.J. PharmTech Res.2010,2(1):264-284

Page 71: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 69

Page 72: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 70

Exp.No: 13 Date :

DISSOLUTION STUDY OF UNCOATED MARKED TABLETS

AIM

To carry out dissolution study of uncoated marketed tablets of paracetamol.

REQUIREMENTS: Paracetamol tabets, rotating paddle type apparatus. Phosphate buffer PH

5.8,UV- Vis spectrophotometer

PREPARATION OF REAGENT:

Phosphate buffer PH

5.8: Take 50ml of 0.2 M potassium di hydrogen phosphate in

200ml volumetric flask to this add 3.6 ml of 0.2 M NaOH and make up to the volume with

distilled water.

PRINCIPLE:

Dissolution is a process in which a solid substance solubilize in a given solvent i.e.,

mass transfer from the solid surface to the liquid phase. Its rate is defines as the amount of

solid substance that goes into solution per unit time under standard condition of temperature,

PH, solvent composition and constant solid surface area.

Noyes and Whitney (1897) and other investigators studied the rate of dissolution of

solid drugs. According to their observations, the steps in dissolution include the process of

drug dissolution at the surface of the solid particle, thus forming a saturated solution around

the particle. The dissolved drug in the saturated solution, known as the stagnant layer,

diffuses to the bulk of the solvent from regions of high drug concentration to regions of low

drug concentration.

According to modified Noyes-Whitney equation

dc/dt = (DA ko/w (Cs –Cb)) / V h

Where, dc/dt = rate of dissolution.Cs-Cb = concentration gradient.

V = volume of distribution. h = thickness of stagnant layer.

Ko/w = partition coefficient. D = diffusion coefficient.

A = surface area of solid.

Page 73: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 71

Page 74: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 72

The Noyes–Whitney equation shows that dissolution in a flask may be influenced by the

physicochemical characteristics of the drug, the formulation, and the solvent. Drug in the

body, particularly in the gastrointestinal tract, is considered to be dissolving in an aqueous

environment. Permeation of drug across the gut wall (a model lipid membrane) is affected by

the ability of the drug to diffuse (D) and to partition between the lipid membranes. A

favourable partition coefficient (K oil/water) will facilitate drug absorption.

In addition to these factors, the temperature of the medium and the agitation rate also

affect the rate of drug dissolution. In vivo, the temperature is maintained at a constant 37°C,

and the agitation (primarily peristaltic movements in the gastrointestinal tract) is reasonably

constant. In contrast, in-vitro studies of dissolution kinetics require maintenance of constant

temperature and agitation. Temperature is generally kept at 37°C, and the agitation or stirring

rate is held to a specified rpm (revolutions per minute). An increase in temperature will

increase the kinetic energy of the molecules and increase the diffusion constant, D. Moreover,

an increase in agitation of the solvent medium will reduce the thickness, h, of the stagnant

layer, allowing for more rapid drug dissolution.

Factors that affect drug dissolution of a solid oral dosage form include (1) the physical

and chemical nature of the active drug substance, (2) the nature of the excipients, and (3) the

method of manufacture.

The best available tool today which can at least quantitatively assure about the

biologic availability of a drug from its formulation is its in vitro dissolution test. For an in

vitro test to be useful, it must predict the in vivo behaviour to such an extent that in vivo

bioavailability test need not be performed. The efforts are mainly aimed at mimicking the

environment offered by the biological system. The dissolution apparatus has evolved

gradually and considerably from a simple beaker type to a highly versatile and fully

automated instrument. Mainly two types of dissolution apparatus are there, rotating basket

and rotating paddle type apparatus.

Page 75: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 73

Page 76: Volume 1 | Issue 1 | Jan - Mar 2013 & Pharmacokinetics · 2016. 4. 2. · Laboratory Manual of Biopharmaceutics and Pharmacokinetics 4 1. Cmax : Peak plasma level computed directly

Laboratory Manual of Biopharmaceutics and Pharmacokinetics 74

PROCEDURE:

Carry out the dissolution test for tablets using 900 ml of phosphate buffer PH 5.8 as

medium.

Rotating the paddle at 50 rpm for 30 minutes withdrawn a suitable volume (1ml) of

the sample.

Filter promptly through a membrane filter disc with an average pore diameter not

greater than 1 micrometre.

Reject the first few ml of the filtrate and dilute a suitable volume of the filtrate with

the same solvent.

Measure the absorbance of the resulting solution at the maximum at about 243nm.

REPORT:

The percentage drug release from given tablet after 30min was found to be

REFERENCES

USP30–NF25 Page 1269 Pharmacopeial Forum : Volume No. 27(3) Page 2495